Spectris plc: Director/PDMR Shareholding
This notification made under Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").
On 27 March 2025, Spectris plc (the "Company") was notified that on the 26 March 2025, Andrew Heath, Chief Executive, and Derek Harding, President, Spectris Scientific acquired 61,399 and 47,808 ordinary shares of 5p each ("Ordinary Shares") in the Company respectively following the exercise of options granted under the terms of the Spectris Long Term Incentive Plan ("LTIP") on 25 March 2020.
Of the 61,399 Ordinary Shares acquired by Mr Heath, 28,994 were sold to fund the option cost and the income tax / national insurance liability at a sale price of £24.1972 and the remaining 32,405 Ordinary Shares were retained and immediately transferred into a nominee account on his behalf.
Of the 47,808 Ordinary Shares acquired by Mr Harding, 22,577 were sold to fund the option cost and the income tax / national insurance liability at a sale price of £24.1972 and the remaining 25,231 Ordinary Shares were retained and immediately transferred into a nominee account on his behalf.
The forms for this transaction, as required under MAR, follows:
| 1 | Details of the persons discharging managerial responsibilities | |
| a) | Name(s) | Andrew Heath, Chief Executive |
| 2 | Reason for the notification | |
| a) | Position/status | Director/PDMR |
| b) | Initial notification/Amendment | Initial Notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Spectris plc |
| b) | LEI | 213800Z4CO2CZO3M3T10 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 5p each
|
| b) | Nature of the transaction | (i) Exercise of options over 61,399 Ordinary Shares under the terms of the LTIP granted on 25 March 2020. (ii) Subsequent sale of 28,994 Ordinary Shares to cover option cost and income tax / national Insurance liabilities arising on exercise. (iii) Transfer of remining 32,405 Ordinary Shares into a nominee account on Mr Heath's behalf.
| ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| (i) Acquisition
£0.05
£0.00
|
54,510 (Share Award granted as a nominal cost option under the terms of the LTIP) 6,889 (Dividend equivalent shares awarded in lieu of dividend accrual on nominal cost option)
| |||
| | | (ii) Sale
£24.1972 |
28,994 | |
| | | (iii) Transfer
£nil |
32,405 | |
| d) | Aggregated information | (i) Acquisition
| ||
| Price per share | £0.0444 | |||
| Volume | 61,399 | |||
| | | Price | £2,725.50 | |
| | | (ii) Sale | ||
| | | Price per share | £24.1972 | |
| | | Volume | 28,994 | |
| | | Price | £701,573.62 | |
| | | (iii) Transfer
| ||
| | | Price per share | £0.0000 | |
| | | Volume | 32,405 | |
| | | Price | £0.00 | |
| e) | Date of the transaction | 26 March 2025
| ||
| f) | Place of the transaction | Outside of a trading venue
| ||
| 1 | Details of the persons discharging managerial responsibilities | ||
| a) | Name(s) | Derek Harding, President Spectris Scientific | |
| 2 | Reason for the notification | ||
| a) | Position/status | Director/PDMR | |
| b) | Initial notification/Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Spectris plc | |
| b) | LEI | 213800Z4CO2CZO3M3T10 | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 5p each
| |
| b) | Nature of the transaction | (i) Exercise of options over 47,808 Ordinary Shares under the terms of the LTIP granted on 25 March 2020. (ii) Subsequent sale of 22,577 Ordinary Shares to cover option cost and income tax / national Insurance liabilities arising on exercise. (iii) Transfer of remaining 25,231 Ordinary Shares into a nominee account on Mr Harding's behalf.
| |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| (i) Acquisition
£0.05
£0.00
|
42,445 (Share Award granted as a nominal cost option under the terms of the LTIP) 5,363 (Dividend equivalent shares awarded in lieu of dividend accrual on nominal cost option)
| ||
| | | (ii) Sale
£24.1972 |
22,577 |
| | | (iii) Transfer
£nil |
25,231 |
| d) | Aggregated information | (iv) Acquisition
| |
| Price per share | £0.0444 | ||
| Volume | 47,808 | ||
| | | Price | £2,122.25 |
| | | (v) Sale | |
| | | Price per share | £24.1972 |
| | | Volume | 22,577 |
| | | Price | £546,300.18 |
| | | (vi) Transfer
| |
| | | Price per share | £0.0000 |
| | | Volume | 25,231 |
| | | Price | £0.00 |
| e) | Date of the transaction | 26 March 2025
| |
| f) | Place of the transaction | Outside of a trading venue
| |
Name of contact and telephone number for queries:
Stephanie Dyer
Group Reward Executive
07386 686 720
For and on behalf of Spectris plc
LEI Number: 213800Z4CO2CZO3M3T10
Date: 27 March 2025
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
